Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Several studies suggest a rising prevalence of HF, which could be attributed to the ageing of the population, along with improved HF survival owing to the tremendous advancement in HF therapy.2–4 In this case study, Dato’ Dr Ahmad Murtazam shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following acute myocardial infarction (AMI) and multiple hospitalisations.
Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
This is the first issue in a series of five
articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data
release. This issue brings insight to the trial’s background, study design and
Heart failure (HF) is a progressive condition where the heart is unable to pump enough blood to meet the body’s needs. Common causes of HF include ischaemic heart disease (IHD), hypertension, cardiomyopathy, diabetes and thyroid disorders. Patients with HF generally require lifelong treatment, but often ask if their medications may be stopped once their symptoms have improved. In this case study, Dato’ Dr Azmee Mohd Ghazi shares his clinical experience treating HF and the current evidence for HF therapy withdrawal.
RB Health is committed to support healthcare quality improvement through CME activities that help physicians stay updated with the latest developments in medicine. At the RB symposium held in Kuala Lumpur, two distinguished speakers gave their insights into the management of acid reflux and sore throat – two of the most common reasons for patients to visit their doctors.
In a dinner symposium organised by Boehringer Ingelheim Malaysia, Dr Alice Cheng spoke on how cardiovascular outcome trials (CVOTs) have evolved and impacted the use of antihyperglycaemic agents such as sodium-glucosecotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical practice.
At the AstraZeneca sponsored-symposium, held in conjunction with Diabetes Asia 2019, a panel of distinguished speakers spoke about the importance of preventing cardiovascular (CV) and renal complications in patients with type 2 diabetes mellitus (T2DM), in addition to addressing glucose control. Chaired by Professor Dato’ Dr Mafauzy Mohamed, the panel discussed updated outcomes of landmark studies supporting the benefit of dapagliflozin (Forxiga®, AstraZeneca) in patients with T2DM.
In a lecture tour series organised by Boehringer Ingelheim Malaysia, Professor Michael Cummings spoke on the latest linagliptin analyses that shed new light on the long-term safety profile of the dipeptidyl peptidase-4 (DPP-4) inhibitor across a broad range of patients with type 2 diabetes (T2D).